Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [5292]

PHOEBE trial results show patients with advanced HER2-positive BC live longer on pyrotinib

PHOEBE trial results show patients with advanced HER2-positive BC live longer on pyrotinib

Metixene breakthrough: A new hope emerges for metastatic brain cancer patients

Metixene breakthrough: A new hope emerges for metastatic brain cancer patients

ESMO 2O23: Major pathologic response to neoadjuvant pembrolizumab in advanced melanoma trial exceeds 50 percent

ESMO 2O23: Major pathologic response to neoadjuvant pembrolizumab in advanced melanoma trial exceeds 50 percent

Lung cancer outcomes significantly improved with immunotherapy-based treatment given before and after surgery

Lung cancer outcomes significantly improved with immunotherapy-based treatment given before and after surgery

Does diabetes affect the survival of individuals with colorectal cancer?

Does diabetes affect the survival of individuals with colorectal cancer?

Skin cancer diagnoses using AI are as reliable as those made by medical experts

Skin cancer diagnoses using AI are as reliable as those made by medical experts

ESMO 2023: Amivantamab plus chemo with or without lazertinib reduced risk of disease progression or death for EGFR-mutated NSCLC

ESMO 2023: Amivantamab plus chemo with or without lazertinib reduced risk of disease progression or death for EGFR...

ESMO 2023: Amivantamab plus lazertinib resulted in 30 percent reduction in risk of disease progression or death compared to osimertinib in patients with EGFR-mutated NSCLC

ESMO 2023: Amivantamab plus lazertinib resulted in 30 percent reduction in risk of disease progression or death...

ESMO 2023: Lutetium (177Lu) vipivotide tetraxetan shows clinically meaningful and highly statistically significant rPFS benefit in patients with PSMA-positive mCRPC in the pre-taxane setting

ESMO 2023: Lutetium (177Lu) vipivotide tetraxetan shows clinically meaningful and highly statistically significant...

ESMO 2023: Kidney cancer study shows improved outcomes for patients with advanced disease when treated with belzutifan over everolimus

ESMO 2023: Kidney cancer study shows improved outcomes for patients with advanced disease when treated with...

More from ecancer